Leading provider of diagnostic tools and information for heart disease and inflammatory disorders selects clinivation WorldView as its most comprehensive, authoritative resource for building its medical product submissions and registrations worldwide.
Natick, MA, December 13, 2007 – clinivation, Inc. announced today that Cholestech Corporation, subsidiary of Inverness Medical Innovations, Inc. (Amex: IMA), has selected clinivation WorldView® Online Regulatory Intelligence web service.
“We are delighted to add Cholestech to the growing list of IVD companies who have selected clinivation WorldView as their source for worldwide regulatory intelligence,” remarked Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions. “Cholestech clearly sees the value on staying current with ever-changing regulations for their global products,” he continued.
Clinivation WorldView is your most comprehensive, authoritative, and up-to-date resource for building all of your medical device submissions and registrations worldwide. Clinivation WorldView also interoperates with clinivation Global® enterprise software to make building and tracking medical device submissions and registrations easier than ever before.
About Cholestech Corporation
Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA waived Cholestech LDX(R) and GDX(TM)* Systems and the hs-CRP test, which is cleared by the FDA for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech’s goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes.
*The GDX system is 510(k) cleared for prescription home use and, accordingly, is CLIA waived.
For additional information, please visit www.cholestech.com.
